Brief: Vicore Pharma Receives Approval To Start Phase IIa Study
April 18 (Reuters) - VICORE PHARMA HOLDING AB VICOR.ST :
* VICORE PHARMA RECEIVES APPROVAL TO START PHASE IIA STUDY
IN IPF
* APPROVAL FROM BRITISH MEDICINES AGENCY MHRA AND ETHICS
COMMITTEE
FOR LONDON AND SURREY FOR PHASE IIA STUDY ON IPF
Source text for Eikon: ID:nWkr3DlQZ5
Further company coverage: VICOR.ST
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Vicore Pharma Holding AB
See all newsBrief: Vicore Pharma Holding Q3 Net Revenues Amounted To Sek 0.6 Mln
Brief: Vicore Pharma Holding AB Phase 2B Aspire Trial Of Buloxibutid In Ipf Passes Pre-Planned Futility Analysis, On Track For Mid-2027 Topline Results
Brief: Vicore Pharma Q2 Operating Loss At SEK 150.1 Million
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:53 PM
Brief: Vicore Pharma Shares Start Trading In US On July 2